Myovant Sciences and Accord Healthcare partner to commercialise Orgovyx in Europe
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
RNA extraction free kit to deliver results in just 45 minutes
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The campaign will be available in nine Indian languages namely Hindi, English, Odia, Marathi, Tamil, Telugu, Kannada, Malayalam and Bengali
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Subscribe To Our Newsletter & Stay Updated